This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Surging Flu Revenue Helps Inverness Post 3Q Profit

WALTHAM, Mass. (AP) ¿ Diagnostics company Inverness Medical Innovations Inc. said Tuesday it turned a profit in the third quarter as sales of flu tests jumped more than fivefold.

Inverness reported a profit of $14.3 million, or 17 cents per share. Leaving out one-time costs such as amortization, restructuring and stock-based compensation, it earned $66.6 million, or 74 cents per share. Inverness lost $9.1 million, or 12 cents per share, a year ago.

According to Thomson Reuters, analysts expected a profit of 61 cents per share, on average. Inverness shares set an annual high of $42.99 Tuesday. In afternoon trading they returned some of their earlier gains, but were still up 68 cents at $40.92.

The company said its net revenue climbed 22 percent to $535.8 million from $438.8 million. That included $40.4 million in North American flu product revenue, compared to $6.8 million a year ago. Inverness also reported $37.4 million in revenue from acquisitions, such as a diagnostic kit business it bought from ACON Laboratories in March, and its recent purchase of Concateno PLC.

Analysts had expected $491.7 million in revenue.

Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AAPL $125.31 -0.84%
FB $83.02 -0.21%
GOOG $554.44 0.44%
TSLA $191.00 0.23%
YHOO $44.98 0.07%

Markets

DOW 17,899.44 -76.87 -0.43%
S&P 500 2,078.80 -7.44 -0.36%
NASDAQ 4,928.3850 -19.0560 -0.39%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs